← Moderna overview

Moderna vs Pfizer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Moderna Inc (MRNA)

Q3 2026
▲3▼1

Moderna hits four-year high on vaccine wins, but risks mount

  • FDA approves mRNA flu vaccine Moderna's mRNA flu vaccine, mFLUSIVA, won FDA approval, opening a new revenue stream and boosting investor confidence in the company's mRNA platform beyond COVID.

    This is a major new product approval that directly drove the stock higher.

  • Melanoma vaccine Phase 3 win A Phase 3 trial of Moderna's melanoma cancer vaccine with Merck succeeded, briefly sending shares up 177% and validating its personalized cancer vaccine approach.

    This is a significant clinical milestone that excited investors about future revenue.

  • Nasdaq 100 inclusion and UAE talks Moderna joined the Nasdaq 100 index and held investment talks with the UAE, adding momentum as index funds bought shares and international interest grew.

    These events increased demand for the stock and broadened its investor base.

  • Setbacks and dilution weigh Vaccine skepticism caused an 11% one-day drop, norovirus trials failed, and a $2.6 billion convertible note raise diluted shareholders, while patent settlements and a Citi downgrade added pressure.

    These negative developments created real counterweights to the positive news.

September 2026
▲2▼2

Moderna hits 4-year high on UAE talks, Nasdaq 100 entry; Citi downgrade and patent suit weigh

  • UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.

    New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.

  • Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.

    New event that creates forced buying by index funds, a direct positive for the stock price.

  • Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.

    New analyst action that directly pushed the stock down and highlights valuation risk.

  • Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.

    New legal development that adds uncertainty and potential cost, weighing on the stock.

Latest
▲2▼2

Moderna hits 4-year high on UAE talks, Nasdaq 100 entry; Citi downgrade and patent suit weigh

  • UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.

    New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.

  • Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.

    New event that creates forced buying by index funds, a direct positive for the stock price.

  • Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.

    New analyst action that directly pushed the stock down and highlights valuation risk.

  • Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.

    New legal development that adds uncertainty and potential cost, weighing on the stock.

August 2026
▲2▼2

Moderna's mRNA flu and cancer wins drive huge but volatile August

  • FDA approves first mRNA flu vaccine The FDA approved mFLUSIVA, Moderna's mRNA flu vaccine, adding a fifth commercial product and validating the platform beyond COVID. This opened a new revenue stream and boosted investor confidence.

    This is a major new approval that directly expands Moderna's product portfolio and revenue potential.

  • Cancer vaccine Phase 3 win with Merck Moderna and Merck's mRNA cancer vaccine intismeran succeeded in a Phase 3 melanoma trial, sending MRNA up as much as 177%. Analysts raised targets, with peak sales forecasts up to $54 billion.

    This is a landmark clinical win that opens a massive new market and was the primary driver of the stock's surge.

  • Norovirus failure and patent payment Moderna's norovirus vaccine failed a Phase 3 interim goal, and the company paid $178 million to settle a patent dispute with Arbutus. These added pipeline uncertainty and legal costs.

    These setbacks weighed on sentiment and highlighted pipeline and legal risks.

  • Dilution and competitive setback Moderna raised $2.6 billion in convertible notes, diluting shareholders and pressuring the stock. BioNTech's colorectal cancer trial failure created negative read-across, and MRNA pulled back 20–23% after its surge.

    These factors contributed to the sharp pullback and reflect financing and competitive risks.

▲4

Moderna's mRNA platform broadens beyond COVID as cancer and flu advance

  • FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.

    This is a new regulatory milestone that expands Moderna's commercial opportunity.

  • Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.

    This is a new pipeline advancement that broadens the platform's application.

  • Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.

    This is the core new event that re-rates Moderna's growth story.

  • Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.

    This shows the market's ongoing positive reaction to the cancer vaccine news.

▲3

Moderna's mRNA platform wins fresh validation as cancer and flu shots advance

  • FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.

    New regulatory approvals directly expand Moderna's product lineup and revenue potential.

  • GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.

    A rival's progress independently validates the mRNA platform Moderna is built on.

  • August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.

    Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

▲2▼1

Moderna's cancer vaccine win reshapes growth story; $2.6B raise and BioNTech stumble add caution

  • First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

    This is the single biggest new event of the period and the core reason MRNA moved.

  • Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.

    Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.

  • $2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.

    This is the main new negative force this period and explains why MRNA fell for three straight sessions.

  • BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.

    This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

▲2▼1

Moderna's mRNA cancer vaccine clears Phase 3, reshaping growth story

  • First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

    This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.

  • Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.

    Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.

  • Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.

    The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.

  • Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.

    This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

▲2▼2

Moderna wins first mRNA flu vaccine approval, but norovirus trial fails

  • FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.

    This is the biggest new event, directly adding a new product and validating the platform.

  • Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.

    This is a new negative event that offsets the flu approval and affects pipeline sentiment.

  • Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.

    This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.

  • Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.

    This is a new cash outflow event that affects Moderna's financial position.

July 2026
▲2▼2

Moderna hits 52-week high on analyst upgrades and pipeline progress

  • Analyst upgrades and Science Day lift shares Piper Sandler raised its price target and Jim Cramer turned positive, while Science Day showcased expansion into cancer, autoimmune treatments, and in vivo CAR-T, pushing shares to a 52-week high.

    This explains the main positive driver of the stock's rise during the period.

  • Q2 beat and flu vaccine decision ahead Q2 results beat estimates with reaffirmed guidance, and an FDA decision on the mRNA-1010 flu vaccine is due August 5, potentially adding a fifth commercial product.

    This highlights fundamental strength and a near-term catalyst that supported the stock.

  • Vaccine skepticism triggers sharp drop Renewed vaccine skepticism caused an 11% one-day drop, showing political and public sentiment risks can still pressure the stock despite improving fundamentals.

    This is a key counterweight that pulled the stock down during the period.

  • Patent settlement and norovirus setback Moderna paid $178 million to Arbutus in a patent settlement, and its norovirus vaccine trial missed an early goal, adding legal costs and pipeline uncertainty.

    These setbacks weighed on the stock and show ongoing legal and pipeline risks.

▲3▼1

Moderna beats Q2, flu shot decision looms, norovirus trial stumbles

  • Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.

    This is the main new financial event of the period and directly affects investor confidence in MRNA.

  • FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.

    This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.

  • Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.

    This is a new negative development that tempers the positive earnings news and highlights pipeline risk.

  • Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.

    This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

▲2▼2

Moderna's mRNA pipeline wins fans, but political and legal clouds linger

  • Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.

    New analyst and media endorsements directly lifted investor sentiment and the stock price.

  • Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.

    The Science Day event was a major catalyst that expanded the growth story and attracted investors.

  • Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.

    This is a new negative development that highlights a real risk to Moderna's core vaccine business.

  • Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.

    This new payment is a concrete financial hit and shows ongoing litigation costs.

Q2 2026
▲3▼1

Moderna's Flu Vaccine Wins FDA Panel, but Patent Settlement Weighs

  • FDA panel backs mRNA flu vaccine An FDA advisory panel unanimously recommended Moderna's mRNA flu vaccine for adults 50 and older, making approval likely in August and opening a new revenue stream.

    This is a major new regulatory milestone that could add a new product to Moderna's lineup.

  • Pipeline expansion and Science Day Moderna plans three vaccine launches by 2028 and showcased cancer, autoimmune, and rare disease programs at its Science Day, boosting investor confidence in its long-term pipeline.

    This highlights new growth opportunities beyond COVID, which is key to the investment case.

  • Q1 revenue surges 260% First-quarter revenue jumped 260% to $389 million, beating analyst estimates, showing a strong rebound in sales.

    This is a new financial result that demonstrates improving business performance.

  • Patent settlement costs $2.25 billion Moderna must pay $2.25 billion to settle patent litigation with Roivant, reducing its financial flexibility and adding a significant cash outflow.

    This is a new negative event that could strain Moderna's finances and limit its ability to invest.

June 2026
▲3▼1

Moderna's Flu Vaccine Wins FDA Panel, but Patent Settlement Weighs

  • FDA panel backs mRNA flu vaccine An FDA advisory panel unanimously recommended Moderna's mRNA flu vaccine for adults 50 and older, making approval likely in August and opening a new revenue stream.

    This is a major new regulatory milestone that could add a new product to Moderna's lineup.

  • Pipeline expansion and Science Day Moderna plans three vaccine launches by 2028 and showcased cancer, autoimmune, and rare disease programs at its Science Day, boosting investor confidence in its long-term pipeline.

    This highlights new growth opportunities beyond COVID, which is key to the investment case.

  • Q1 revenue surges 260% First-quarter revenue jumped 260% to $389 million, beating analyst estimates, showing a strong rebound in sales.

    This is a new financial result that demonstrates improving business performance.

  • Patent settlement costs $2.25 billion Moderna must pay $2.25 billion to settle patent litigation with Roivant, reducing its financial flexibility and adding a significant cash outflow.

    This is a new negative event that could strain Moderna's finances and limit its ability to invest.

▲3

Moderna's pipeline beyond COVID wins investor confidence

  • Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.

    This is the main new event of the period and directly explains the stock's surge.

  • FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.

    This is a new regulatory milestone that de-risks a key product and supports the stock's rise.

  • Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.

    This new earnings data provides fundamental support for the stock's recent gains.

  • Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.

    This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

▲2▼1

Moderna's flu vaccine wins FDA panel backing, but patent settlement costs $2.25B

  • FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.

    This is the main new event that directly lifts MRNA's price by de-risking a major product approval.

  • Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.

    This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.

  • Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.

    This new settlement is a significant negative financial event that weighs on MRNA's price.

Pfizer Inc (PFE)

Q3 2026
▲3▼1

Pfizer gains on pricing deal, raised guidance, pipeline progress

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary deal on drug pricing, reducing the threat of new regulations. This lowers uncertainty and helps the company plan without fear of sudden price controls.

    It was a major positive event that reduced regulatory overhang and boosted investor confidence.

  • Q2 earnings beat and 2026 guidance raised Pfizer reported better-than-expected second-quarter results and raised its full-year 2026 revenue forecast to $60.5–$62.5 billion. This signals stronger business performance than previously thought.

    Earnings beats and raised guidance are key drivers of stock price and show improving fundamentals.

  • Cost cuts expanded, pipeline reaches 95 programs Pfizer increased its cost-cutting target to $2.5 billion and now has 95 pipeline programs. Label expansions and new bets in obesity, oncology, Lyme, eczema, and vitiligo aim to boost future revenue.

    Cost savings and pipeline growth are positive for future earnings and show management action.

  • Patent expirations, competition, and debt weigh on outlook Upcoming patent expirations for Ibrance and Eliquis, pricing pressure, Moderna’s new approvals, $60.5 billion debt, and a thinly covered dividend pose risks. Growth was only 1% with a net loss.

    These are significant headwinds that could limit upside and pressure the stock.

September 2026
▲2▼2

Pfizer advances pipeline but faces competition, legal, and financial risks

  • Pipeline and new product momentum Pfizer is advancing growth bets in oncology, obesity, and new drugs like eczema treatment tilrekimig and vitiligo therapy LITFULO. Pipeline programs reached 95, and international new-product sales climbed to $4 billion, showing progress in diversifying beyond COVID.

    This highlights the key positive development that could drive future revenue growth.

  • Cost cuts and productivity gains Cost cuts and tripled sales-force productivity help offset shrinking COVID revenue. This efficiency improvement supports profitability despite top-line pressures.

    This shows management's efforts to improve financial health, a positive factor for the stock.

  • Intensifying competition and guidance concerns Moderna's new COVID and mRNA flu approvals intensify competition, while 2026 guidance sits below 2025 amid patent expirations. This creates uncertainty about Pfizer's ability to grow revenue.

    This is a major negative factor weighing on investor sentiment and future earnings.

  • Financial and legal risks The 6.19% dividend is thinly covered by free cash flow alongside $60.5 billion in debt. Overseas revenue-sharing under the most-favored-nation deal caps pricing upside through 2029, and Monsanto's mRNA patent lawsuit survived dismissal, creating legal and financial uncertainty.

    These factors pose significant risks to Pfizer's financial stability and stock performance.

Latest
▲2▼2

Pfizer's pipeline wins offset pricing and patent setbacks

  • Overseas revenue sharing caps pricing upside Pfizer must share part of any extra overseas drug revenue with the U.S. government under its most-favored-nation pricing deal, running through early 2029. This limits how much Pfizer can profit from higher prices abroad, a direct hit to future earnings and a drag on the stock.

    New pricing rule directly reduces Pfizer's overseas profit potential.

  • New products and cost cuts offset COVID decline Pfizer said new and acquired medicines, vaccines and oncology products grew from $500 million in 2023 to $4 billion internationally, with $3.2 billion in Q2 alone. It also cut costs and tripled sales-force productivity, showing the growth story is delivering as COVID revenue shrinks.

    Shows the core strategy replacing lost COVID revenue is working.

  • Pipeline wins in eczema and vitiligo Pfizer's eczema drug tilrekimig met its Phase 2 goal with strong skin clearance, and LITFULO hit Phase 3 targets in vitiligo, with regulatory filings planned. These are new growth candidates beyond COVID, supporting the long-term pipeline story investors are counting on.

    Two positive trial results add fresh pipeline value beyond existing drugs.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected Pfizer's bid to dismiss Monsanto's mRNA patent infringement lawsuit over its COVID-19 vaccines. The case now proceeds, creating legal uncertainty and potential financial liability that could weigh on the stock until resolved.

    New legal setback adds uncertainty and potential cost for Pfizer.

▲2▼2

Pfizer's growth bets advance as cash and patent worries weigh

  • Moderna's new approvals add COVID and flu competition Moderna won FDA approval for updated COVID shots and the first mRNA flu vaccine for older adults. That means more rivals fighting for the same pharmacy shelf space and patient visits, which can pressure Pfizer's COVID vaccine sales and slow its push into flu.

    New competitive threat directly affecting Pfizer's respiratory vaccine revenue.

  • Oncology sales and pipeline strengthen Pfizer's cancer business grew 3% to $4.17 billion last quarter, led by Padcev, up 23%, after an FDA approval expanded its patient pool. Pfizer is also testing a promising new cancer drug and aims for eight or more blockbuster cancer medicines by 2030, giving investors a concrete growth engine.

    Shows a real, current revenue driver offsetting declines elsewhere.

  • Obesity and oncology pipeline is the growth story Pfizer now has 95 pipeline programs, with the biggest bets in obesity and cancer. Its monthly obesity shot berobenatide could launch around 2028 in a market expected to reach $114 billion. Progress here is what investors are counting on to replace lost COVID and patent revenue.

    Explains the long-term growth thesis that supports the stock.

  • Dividend and 2026 guidance under pressure Pfizer's 6.19% dividend is only thinly covered by free cash flow, with $60.5 billion of debt competing for the same cash. Management also guided 2026 revenue and earnings below 2025 levels as COVID sales collapse and patents expire. That combination limits financial flexibility and keeps a lid on the stock.

    Highlights the main financial risk weighing on Pfizer's valuation.

August 2026
▲3▼1

Pfizer raises guidance, cuts costs, advances pipeline despite patent and pricing risks

  • Guidance raised on non-COVID drugs Pfizer lifted its 2026 revenue outlook by $500 million, driven by strong sales of non-COVID medicines. This signals that the core business is growing faster than expected, giving investors more confidence in future earnings.

    This is a new positive development that directly boosts investor confidence and is a key reason for the stock's movement.

  • Cost cuts expanded to $2.5 billion Pfizer widened its cost-cutting program to save an additional $2.5 billion. Lower expenses can protect profits even if sales slow, and the move shows management is taking action to improve financial health.

    This is a new operational improvement that supports profitability and is likely to be viewed positively by investors.

  • Pipeline advances: Lyme vaccine and obesity drug Pfizer moved forward its Lyme disease vaccine and obesity drug berobenatide, which could reach the market by 2028. These new products offer future revenue streams as older drugs face patent expirations.

    This is a new pipeline update that addresses long-term growth concerns and is a positive catalyst for the stock.

  • Patent lawsuits and pricing pressure persist Arbutus lawsuits over lipid nanoparticle technology add legal costs and uncertainty, while U.S. drug pricing pressure continues. Overall growth was just 1% with a net loss, and major drugs face patent expirations through 2030.

    These are ongoing risks that weigh on the stock and are important for a balanced view, even though some elements were previously known.

▲3▼1

Pfizer's pipeline advances, but pricing and patent worries persist

  • Obesity drug berobenatide targets 2028 approval Pfizer's lead obesity drug berobenatide is advancing in late-stage trials, with a potential 2028 approval. It aims to compete in a market expected to reach $114 billion by 2030. This offers a major new growth path as older drugs lose patent protection, supporting the stock.

    This is a new pipeline update that could drive future revenue growth, directly answering what's moving PFE.

  • Eliquis strength lifts partner Bristol Myers' outlook Bristol Myers raised its 2026 revenue guidance after Eliquis sales grew 19% in the first half. Pfizer co-markets Eliquis, so it shares in these profits. Stronger-than-expected sales mean more cash for Pfizer, helping offset declines elsewhere and supporting the stock.

    This new update shows a key Pfizer product performing well, directly boosting Pfizer's revenue outlook.

  • FDA approves updated COVID vaccine, EMA reviews Lyme shot The FDA approved Pfizer's XFG-adapted COVID vaccine for high-risk groups, allowing immediate U.S. distribution. Separately, the EMA validated Pfizer's Lyme disease vaccine application. These regulatory wins support near-term COVID sales and add a potential new vaccine revenue stream.

    These are new regulatory milestones that directly affect Pfizer's product sales and pipeline prospects.

  • Drug pricing pressure and patent cliff concerns linger The Trump administration is expected to announce a drug pricing agreement with mid-sized biotech firms, and Pfizer was among major companies urged to cut U.S. prices. Meanwhile, Pfizer's total growth was only 1% and it posted a net loss, with major drugs facing patent expirations through 2030.

    This highlights ongoing regulatory and competitive pressures that could weigh on Pfizer's future revenue and stock.

▲3▼1

Pfizer lifts guidance on non-COVID strength, adds cost savings and Lyme vaccine milestone

  • Pfizer raises 2026 revenue guidance on non-COVID drugs Pfizer beat Q2 estimates and raised its 2026 revenue forecast by $500 million to $60.5–$62.5 billion, driven by strong non-COVID products. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the main new positive event of the period and directly boosts investor confidence in Pfizer's growth.

  • Pfizer expands cost-cutting, expects $2.5 billion extra savings Pfizer announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, raising total net savings to about $9.7 billion. Lower costs improve future profits and cash flow, which supports the stock.

    This is a new financial development that improves Pfizer's profitability outlook and helps fund its dividend.

  • EMA validates Pfizer-Valneva Lyme disease vaccine application The European Medicines Agency validated the marketing application for Pfizer and Valneva's Lyme disease vaccine candidate, based on Phase 3 efficacy above 70%. If approved, it could be the first such vaccine in Europe, adding a new revenue stream and supporting the stock.

    This is a new regulatory milestone that advances a potential new vaccine product for Pfizer.

  • Arbutus patent lawsuits over lipid nanoparticle technology persist Arbutus filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in COVID vaccines. This adds legal costs and uncertainty, weighing on the stock.

    This is a new legal development that creates ongoing risk and potential financial liability for Pfizer.

July 2026
▲3▼1

Pfizer gains on pricing deal, earnings beat, label wins

  • Voluntary drug-pricing deal cuts regulatory risk Pfizer struck a voluntary drug-pricing agreement with the Trump administration, easing the threat of forced price cuts. For investors, this lowers a major regulatory overhang and makes future revenue more predictable.

    This is a new, company-specific policy development that reduces a key risk for Pfizer.

  • Q2 earnings beat and raised 2026 guidance Pfizer reported second-quarter results above expectations and raised its full-year 2026 revenue outlook to $60.5–$62.5 billion. The beat and guidance hike signal stronger business momentum than previously thought.

    This is a fresh financial update that directly boosts investor confidence in Pfizer's near-term performance.

  • Label expansions and pipeline advances Pfizer won FDA label expansions for Ibrance and Padcev, got priority review for TALZENNA plus XTANDI, and advanced vitiligo and obesity programs. These broaden existing drugs' use and add future revenue sources.

    These are new regulatory and pipeline wins that expand Pfizer's commercial opportunities.

  • Patent lawsuits and patent-cliff worries persist International patent lawsuits over Comirnaty's lipid nanoparticles and upcoming 2027–2028 expirations for Ibrance and Eliquis keep weighing on Pfizer. These legal and patent risks threaten future sales and create uncertainty.

    This is a new legal development and a continuing overhang that pressures the stock.

▲3▼1

Pfizer's non-COVID drugs and pipeline progress offset COVID decline and patent cliff worries

  • Q2 earnings beat and raised revenue guidance Pfizer beat profit estimates and raised the low end of its 2026 revenue forecast to $60.5–$62.5 billion, driven by strong non-COVID drugs like Eliquis, Padcev, and Vyndaqel. This shows the core business is growing and helps offset declining COVID sales, supporting the stock.

    This is the period's biggest positive catalyst, directly boosting investor confidence in Pfizer's financial outlook.

  • Pipeline wins: LITFULO vitiligo and berobenatide obesity data Pfizer reported positive Phase 3 results for LITFULO in vitiligo and Phase 2b data showing its weight-loss drug berobenatide achieved 16% weight loss. These advance Pfizer's pipeline into new markets, offering future growth to replace aging drugs.

    These pipeline successes are new and show Pfizer's ability to develop new revenue sources, which is key to offsetting the patent cliff.

  • FDA priority review for TALZENNA+XTANDI and EU COVID vaccine authorization The FDA granted priority review to Pfizer's TALZENNA+XTANDI for earlier-stage prostate cancer, and the EU authorized Pfizer's updated COVID-19 vaccine. These regulatory milestones expand market opportunities and support sales in the near term.

    Regulatory progress is a new positive development that can lead to additional revenue streams and shows Pfizer's ability to navigate approvals.

  • Dividend strain and patent cliff concerns persist Pfizer's dividend payout exceeded 130% of earnings, raising concerns about financial strain as major drugs like Ibrance and Eliquis face patent expirations in 2027–2028. Management reaffirmed the dividend, but the high yield reflects investor worries about future cash flows.

    This is a key counterweight to the positive news, highlighting the financial challenges that could pressure the stock if not addressed.

▲3▼1

Pfizer's pipeline wins and pricing deals offset COVID decline and patent cliff

  • FDA approvals expand Ibrance and Padcev labels The FDA approved Ibrance for a new breast cancer type and Padcev with Keytruda for bladder cancer. These label expansions grow Pfizer's oncology sales and help replace falling COVID revenue, supporting the stock.

    New regulatory wins directly boost Pfizer's revenue outlook and investor confidence.

  • Competitor's ATTR-CM trial failure lifts Vyndamax AstraZeneca's ATTR-CM drug failed a late-stage trial, removing a potential rival to Pfizer's Vyndamax. This reduces competition for a $5.4 billion franchise, making Pfizer's rare-disease business more durable.

    Less competition protects a key Pfizer product's sales and pricing power.

  • Voluntary drug-pricing deal with Trump administration Pfizer signed a most-favored-nation pricing agreement, offering discounts on 30+ drugs. While it lowers some prices, it avoids harsher mandates and expands direct-to-consumer sales, providing clarity and reducing regulatory risk.

    The deal removes a major overhang and shows Pfizer adapting to new pricing rules.

  • Patent lawsuits over COVID vaccine technology Arbutus and Roivant filed international patent suits against Pfizer over lipid nanoparticles in Comirnaty, seeking injunctions and damages. This adds legal costs and uncertainty, weighing on the stock.

    New litigation creates financial risk and potential disruption to a major product.

Q2 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

June 2026
▼3▲1

Pfizer's mixed June: pipeline wins, leadership exit, policy setback

  • Obesity injection enters late-stage testing Pfizer moved its monthly obesity injection berobenatide into Phase 3 trials, aiming for approval in 2028 in a market that could be worth $120 billion. This gives the company a shot at a big new revenue source.

    This is a major pipeline advance that could drive future growth.

  • Lung cancer trial failure hits Seagen pipeline A Phase 3 trial of sigvotatug vedotin in lung cancer failed, raising doubts about the $43 billion Seagen acquisition. Pfizer shares fell 7.3% on the news, reflecting investor concern about the company's cancer drug prospects.

    This was a significant negative event that directly moved the stock price.

  • CFO departure creates uncertainty Pfizer's Chief Financial Officer is leaving in August, leaving a gap in financial leadership. For investors, a change at the top finance job can raise questions about strategy and execution.

    Leadership changes can affect investor confidence and future direction.

  • COVID drug emergency authorizations ended The termination of COVID-19 drug emergency use authorizations, associated with RFK Jr., reduces sales of Pfizer's Paxlovid. This policy shift cuts into a previously reliable revenue stream.

    This regulatory change directly impacts Pfizer's COVID product sales.

▲3▼1

Pfizer's obesity pipeline and cheap valuation drive the story

  • Pfizer pushes into next-gen obesity drugs with monthly dosing Pfizer aims to lead in next-generation obesity therapies with monthly dosing, advancing 10 phase 3 studies and targeting 2028 approval. This is a huge potential market, and success could add a major new growth engine, pushing the stock up.

    This is a key new positive development that could drive future revenue growth.

  • Pfizer seen as deep value with potential to double in 3-5 years Pfizer is viewed as a deep value opportunity, trading at a low P/E with a 6.5% dividend yield. Bulls point to the Seagen acquisition, GLP-1 pipeline, and over 20 Phase 3 trials as catalysts that could double the stock over three to five years.

    This highlights the investment case and potential upside, attracting value investors.

  • RFK Jr. ends COVID-19 drug EUAs, hitting Paxlovid sales HHS Secretary RFK Jr. terminated Emergency Use Authorizations for COVID-19 drugs, including Pfizer's Paxlovid. This reduces future sales of the treatment, weighing on revenue and the stock price.

    This is a new regulatory setback that directly impacts a Pfizer product.

  • Pfizer's strong balance sheet fuels acquisition hopes CEO Albert Bourla says Pfizer has a very big balance sheet and can pursue transformative acquisitions. The company could deepen its weight loss portfolio by acquiring Kailera Therapeutics, signaling financial strength and deal capacity.

    This shows Pfizer's ability to grow through M&A, which could boost future earnings.

▲2▼2

Pfizer's mixed pipeline news: obesity bet advances, cancer drug fails, CFO exits

  • CFO departure adds uncertainty Pfizer's CFO Dave Denton will leave on August 15, raising questions about financial leadership and the 2026 outlook. Shares fell on the news. A new CFO search adds near-term uncertainty, which can weigh on the stock until a permanent replacement is named.

    This is a new event that directly affects investor confidence in Pfizer's financial strategy.

  • Lung cancer drug fails Phase 3 trial Pfizer's sigvotatug vedotin did not significantly improve overall survival in a Phase 3 lung cancer trial. The drug came from the $43 billion Seagen acquisition. This setback raises doubts about the Seagen pipeline and pushed the stock down 7.3% on June 25.

    This is a major clinical failure that impacts Pfizer's oncology growth story and investor sentiment.

  • Obesity pipeline advances with monthly injection Pfizer is moving berobenatide into Phase 3 trials, aiming for 2028 approval. It's a monthly GLP-1 shot for obesity, a market expected to reach $120 billion by 2035. Positive Phase 2b data and over 20 planned studies give Pfizer a shot at a lucrative new market.

    This is a new pipeline update that could drive future revenue growth and offsets negative news.

  • IBRANCE approved for expanded breast cancer use The FDA approved IBRANCE for a new type of metastatic breast cancer, making it the first CDK4/6 inhibitor for both HR+ and HER2+ patients. This expands the market for an existing drug and helps offset pipeline setbacks.

    This is a new regulatory approval that strengthens Pfizer's oncology franchise and provides a revenue boost.

© 2026 MarketIVWhy